Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation | DelveInsight
The Pompe disease market is estimated to change significantly during the forecast period (2026–2036), owing to the launch of novel therapies including MZE001 (S-606001; Shionogi and Maze Therapeutics), AT845 (Astellas Pharma), AB-1009 [AskBio (Bayer)], DNL952 (Denali Therapeutics), ABX1100 (Aro Biotherapeutics), GC301 (GeneCradle), and others, and the continued uptake of approved therapies.
LAS VEGAS, Oct. 13, 2026 /PRNewswire/ -- Recently published Pompe Disease Market Insights report includes a comprehensive understanding of current treatment practices, Pompe disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Pompe Disease Market Summary
- The total Pompe Disease treatment market size is expected to grow positively by 2036 in the leading markets.
- The United States accounted for the largest Pompe disease treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- The United States accounted for the largest share, approximately 66%, of the diagnosed prevalent cases of Pompe disease among the 7MM in 2025, while Spain had the lowest prevalence.
- Leading Pompe disease companies, such as Shionogi, Maze Therapeutics, Astellas Pharma, AskBio (Bayer), Denali Therapeutics, Aro Biotherapeutics, GeneCradle, and others, are developing new Pompe disease treatment drugs that can be available in the Pompe disease market in the coming years.
- The promising Pompe disease therapies in clinical trials include MZE001 (S-606001), AT845, AB-1009, DNL952, ABX1100, GC301, and others.
Discover Pompe disease life expectancy with treatment @ https://www.delveinsight.com/report-store/pompe-disease-market
Key Factors Driving the Growth of the Pompe Disease Market
- Rising Disease Awareness and Diagnosis: Greater awareness of Pompe disease among healthcare professionals and patients is supporting earlier identification of the condition. Advances in newborn screening and diagnostic testing are also helping detect previously underdiagnosed cases.
- Increasing Adoption of Enzyme Replacement Therapy: ERT remains a key treatment approach for Pompe disease, particularly for improving survival and disease management. Continued use of approved therapies is supporting market demand, while treatment optimization is expanding the addressable patient population.
- Growing Newborn Screening Programs: Expansion of newborn screening initiatives is enabling earlier detection of infantile-onset Pompe disease before severe symptoms develop. Earlier diagnosis can facilitate prompt treatment initiation and improve clinical management.
- Expansion of Genetic and Molecular Diagnostics: Advances in genetic testing are making it easier to confirm GAA gene mutations and distinguish Pompe disease from other neuromuscular disorders. Improved diagnostic capabilities are enabling earlier, more accurate patient identification.
- Increasing Clinical Research and Pipeline Activity: Growing investment in Pompe disease research is driving the development of novel therapeutic candidates including MZE001 (S-606001; Shionogi and Maze Therapeutics), AT845 (Astellas Pharma), AB-1009 [AskBio (Bayer)], DNL952 (Denali Therapeutics), ABX1100 (Aro Biotherapeutics), GC301 (GeneCradle), and others. Clinical trials targeting both infantile- and late-onset disease are strengthening the future market pipeline.
Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said MZE001 could be used as a monotherapy or as an add-on to enzyme replacement therapy, the current standard of care, to improve treatment for patients with Pompe disease.
Pompe Disease Market Analysis
- Treatment for Pompe disease is disease-specific, symptomatic, and supportive, and requires a coordinated, multidisciplinary approach involving specialists experienced in managing neuromuscular disorders.
- Enzyme Replacement Therapy (ERT) remains the mainstay of treatment and involves administering a synthetic form of the deficient Acid Alpha-glucosidase (GAA) enzyme to compensate for the enzyme deficiency.
- Approved therapies for Pompe disease include POMBILITI + OPFOLDA (Amicus Therapeutics), NEXVIAZYME (Sanofi), and LUMIZYME/MYOZYME (Sanofi).
- For many years after its approval, LUMIZYME/MYOZYME remained the standard of care for patients with Pompe disease.
- While the treatment has been lifesaving, many patients receiving LUMIZYME/MYOZYME infusions continue to experience disease progression and require higher doses, highlighting the persistent unmet need in Pompe disease management.
- The second-generation ERT, NEXVIAZYME, was developed to achieve greater uptake into target cells, thereby enhancing the therapeutic response.
- Since its licensure, patients have increasingly transitioned from LUMIZYME/MYOZYME to NEXVIAZYME to improve clinical outcomes and help prevent further disease decline.
- The Pompe disease pipeline includes several potential therapies in development. Companies such as Shionogi and Maze Therapeutics (MZE001 [S-606001]), Astellas Pharma (AT845), Aro Biotherapeutics (ABX1100), and AskBio/Bayer (AB-1009) are actively pursuing research and development programs for Pompe disease.
Pompe Disease Competitive Landscape
Some of the Pompe disease medications under development include MZE001 (S-606001; Shionogi and Maze Therapeutics), AT845 (Astellas Pharma), AB-1009 [AskBio (Bayer)], DNL952 (Denali Therapeutics), ABX1100 (Aro Biotherapeutics), GC301 (GeneCradle), and others.
Shionogi and Maze Therapeutics' MZE001 is an oral glycogen synthase (GYS1) inhibitor being developed to treat Pompe disease by reducing the accumulation of disease-causing glycogen. The U.S. FDA has granted MZE001 Rare Pediatric Disease Designation (RPDD).
Astellas Pharma's AT845 is an investigational AAV-based gene replacement therapy designed to deliver a functional copy of the GAA gene directly to muscle cells in adults with late-onset Pompe disease (LOPD). The company has also entered into an exclusive licensing and development agreement for IdeXork (Xork), a potential next-generation immunoglobulin G (IgG) protease. Astellas will develop Xork for use in combination with AT845 as a treatment for adults with LOPD.
Genecradle Therapeutics' GC301 is an investigational Pompe disease therapy that uses an AAV vector to deliver a GAA gene expression cassette. Administered as a single intravenous injection, GC301 is designed to systemically compensate for GAA enzyme deficiency and target key affected tissues, including the liver, heart, skeletal muscle, and central nervous system. A single dose is intended to support long-term GAA enzyme expression, with the potential to improve motor function and quality of life while addressing the underlying cause of Pompe disease.
The anticipated launch of these emerging therapies are poised to transform the Pompe disease market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Pompe disease market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the Pompe disease treatment market @ Pompe Disease Therapy
Recent Developments in the Pompe Disease Market
- In June 2026, Sanofi announced positive results from the Baby-COMET Phase 3, single-arm, open-label study (NCT04910776), showing that Nexviazyme (avalglucosidase alfa) achieved its primary endpoint. The endpoint assessed the proportion of treatment-naïve pediatric participants aged six months or younger with infantile-onset Pompe disease (IOPD) who remained alive and free from invasive ventilation after 52 weeks of treatment.
- In May 2026, AskBio Inc. announced that the first participant has been dosed with investigational gene therapy AB-1009 in the PROGRESS-GT LOPD Phase 1/2 clinical trial evaluating the treatment in participants with late-onset Pompe disease (LOPD).
- In March 2026, Shionogi & Co., Ltd. announced the enrollment of the first patients in Esprit, a global Phase 2 clinical trial evaluating investigational S-606001 for the treatment of late-onset Pompe disease (LOPD).
- In March 2026, Aro Biotherapeutics announced positive topline results from the Phase 1b portion of its clinical trial evaluating ABX1100, an investigational novel therapy for the treatment of late-onset Pompe disease (LOPD).
Pompe Disease Epidemiology Segmentation
The Pompe disease epidemiology section provides insights into the historical and current Pompe disease patient pool and forecasted trends for the leading markets. Approximately 70% of cases comprise late-onset Pompe disease, whereas only 30% of cases comprise infantile-onset Pompe disease in the US.
The Pompe disease treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
- Total Live Birth Cases of Pompe Disease
- Total Adult Cases of Pompe Disease
- Onset-specific Diagnosed Prevalent Cases of Pompe Disease
- Total Prevalent Cases of IOPD by Clinical Phenotypes
- Treated Cases of Pompe Disease
Pompe Disease Market Report Metrics | Details |
Study Period | 2022–2036 |
Coverage | 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. |
Pompe Disease Epidemiology Segmentation | Total Live Birth Cases of Pompe Disease, Total Adult Cases of Pompe Disease, Onset-specific Diagnosed Prevalent Cases of Pompe Disease, Total Prevalent Cases of IOPD by Clinical Phenotypes, and Treated Cases of Pompe Disease |
Key Pompe Disease Companies | Shionogi, Maze Therapeutics, Astellas Pharma, AskBio (Bayer), Denali Therapeutics, Aro Biotherapeutics, GeneCradle, Sanofi, Amicus Therapeutics, and others |
Key Pompe Disease Therapies | MZE001 (S-606001), AT845, AB-1009, DNL952, ABX1100, GC301, LUMIZYME/MYOZYME, NEXVIAZYME, POMBILITI + OPFOLDA, and others |
Scope of the Pompe Disease Market Report
- Pompe Disease Patient Population Forecast
- Pompe Disease Therapeutics Market Size
- Pompe Disease Pipeline Analysis
- Pompe Disease Market Size and Trends
- Pompe Disease Market Opportunity
- Pompe Disease Market Unmet Needs
- KOL's Views on Pompe Disease
- Pompe Disease Market Access and Reimbursement
Download the report to understand the Pompe disease treatment pipeline @ Pompe Disease Drugs
Table of Contents
1 | Pompe Disease Market Key Insights |
2 | Pompe Disease Market Report Introduction |
3 | Executive Summary |
4 | Key Events |
5 | Epidemiology and Market Forecast Methodology |
6 | Pompe Disease Market Overview at a Glance |
6.1 | Clinical Landscape Analysis (by Phase, Route of Administration, and Mechanism of Action) |
6.2 | Market Share by Therapies (%) Distribution of Pompe Disease in 2025 in the 7MM |
6.3 | Market Share by Therapies (%) Distribution of Pompe Disease in 2036 in the 7MM |
7 | Disease Background and Overview |
7.1 | Introduction to Bronchiectasis |
7.2 | Etiology |
7.3 | Clinical Features |
7.4 | Signs and Symptoms |
7.5 | Pathophysiology |
7.6 | Diagnosis |
7.7 | Treatment |
8 | Epidemiology and Patient Population |
8.1 | Key Findings |
8.2 | Assumptions and Rationale: The 7MM |
8.2.1 | Total Diagnosed Prevalent Cases of Pompe Disease in the 7MM |
8.3 | The US |
8.3.1 | Total Live Birth Cases of Pompe Disease in the US |
8.3.2 | Total Adult Cases of Pompe Disease in the US |
8.3.3 | Onset-specific Diagnosed Prevalent Cases of Pompe Disease in the US |
8.3.4 | Total Prevalent Cases of IOPD by Clinical Phenotypes (CRIM Positive, and CRIM Negative) in the US |
8.3.5 | Treated Cases of Pompe Disease in the US |
8.4 | EU4 and the UK |
8.5 | Japan |
9 | Patient Journey |
10 | Marketed Pompe Disease Drugs |
10.1 | Key Cross Competition |
10.2 | NEXVIAZYME: Sanofi |
10.2.1 | Product Description |
10.2.2 | Regulatory Milestone |
10.2.3 | Other Development Activities |
10.2.4 | Current Pipeline Activity |
10.2.4.1 | Clinical Trials Information |
10.2.5 | Safety and Efficacy |
10.2.6 | Analyst's View |
10.3 | POMBILITI (cipaglucosidase alfa) and OPFOLDA (miglustat): Amicus Therapeutics |
List of drugs to be continued in the report… | |
11 | Emerging Pompe Disease Drugs |
11.1 | Key Cross Competition |
11.2 | AT845: Astellas Pharma |
11.2.1 | Product Description |
11.2.2 | Other Development Activities |
11.2.3 | Clinical Development |
11.2.3.1 | Clinical Trial Information |
11.2.4 | Safety and Efficacy |
11.2.5 | Analyst's View |
11.3 | ACTUS-101: Bayer AG/Asklepios BioPharmaceutical |
11.4 | MZE001 (S-606001): Shionogi and Maze Therapeutics |
List of drugs to be continued in the report… | |
12 | Pompe Disease Market: Seven Major Market Analysis |
12.1 | Key Findings |
12.2 | Pompe Disease Market Outlook |
12.3 | Conjoint Analysis |
12.4 | Key Pompe Disease Market Forecast Assumptions |
12.5 | Total Market Size of Pompe Disease in the 7MM |
12.6 | The United States Pompe Disease Market |
12.6.1 | Total Market Size of Pompe Disease in the US |
12.6.2 | Market Size of Pompe Disease by Therapies in the US |
12.7 | EU4 and the UK Pompe Disease Market |
12.8 | Japan |
13 | Key Opinion Leaders' Views |
14 | SWOT Analysis |
15 | Unmet Need |
16 | Market Access and Reimbursement |
16.1 | The United States |
16.2 | EU4 and the UK |
16.3 | Japan |
16.4 | Summary and Comparison of Market Access and Pricing Policy Developments in 2025 |
16.5 | Market Access and Reimbursement of Pompe Disease |
17 | Bibliography |
18 | Pompe Disease Market Report Methodology |
Related Reports
Pompe Disease Clinical Trial Analysis
Pompe Disease Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Pompe disease companies, including Shionogi & Co., Ltd., Astellas Gene Therapies, Bayer AG, Ask Bio, Denali Therapeutics Inc., Gene Cradle Therapeutics, Aro Biotherapeutics, Genethon, M6P Therapeutics, Dyne Therapeutics, Fortress Biotech, AVROBIO, and others.
Glycogen Storage Disease Market
Glycogen Storage Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glycogen storage disease companies, including Sanofi, Ultragenyx Pharmaceutical, Amicus Therapeutics, Astellas Pharma, Spark Therapeutics, Maze Therapeutics, Takeda Pharmaceutical, Merck, Novartis, Boehringer Ingelheim, and others.
Fabry Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Fabry disease companies, including Amicus Therapeutics, CHIESI Farmaceutici, Protalix Biotherapeutics, Sanofi (Genzyme), Takeda Pharmaceuticals, Sangamo Therapeutics, UniQure Biopharma, Idorsia Pharmaceuticals, Sangamo Therapeutics, AceLink Therapeutics, Glafabra Therapeutic, and others.
Niemann-Pick Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Niemann-Pick disease companies, including Azafaros A.G., Cyclo Therapeutics, Inc., ZevraDenmark, Genzyme, Mandos Health, Zevra Therapeutics, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us:
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Share this article